Season 2 - Ep. 2: LV non-compaction / Excessive LV trabeculation - GLP1-receptor agonists: the next revolution in heart disease?

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies GLP1-Receptor Agonists - the next revolution in heart disease? Left-ventricular non-compaction or excessive left-ventricular trabeculation Snapshots Host: Susanna Price Guests: Stephan Achenbach, Carlos Aguiar, Ulrich Laufs and Steffen Petersen. Want to watch that episode? Go to: https://esc365.escardio.org/event/1137   Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Nicolle Kraenkel, Ulrich Laufs and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy to Circle Cardiovascular Imaging. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.